J Rheum Dis.  2022 Oct;29(4):200-214. 10.4078/jrd.22.0029.

Epidemiology and Treatment of Systemic Sclerosis in Korea

• Lee SG
• Moon KW

• KMID: 2533621
• DOI: http://doi.org/10.4078/jrd.22.0029

Abstract

Systemic sclerosis (SSc), a rare, chronic progressive systemic autoimmune disease of unknown etiology, is characterized by autoimmunity, tissue fibrosis, and obliterative vasculopathy. SSc can affect all major organs including the skin, blood vessels, lung, heart, kidneys, and gastrointestinal tract. Our understanding of its pathogenesis has increased over the past few decades, leading to improved diagnosis and treatment. However, the mortality rate of SSc remains considerable, mainly due to cardiopulmonary causes. A growing body of evidence suggests that geographical, regional, and ethnic differences could affect the epidemiology, clinical characteristics and prognosis of SSc. Although Korean data of this issue are lacking, a considerable amount of research has been published by many Korean researchers. To establish treatment strategies for Korean patients, extensive Korean research data are needed. This review summarizes the prevalence, incidence, mortality, and clinical and laboratory manifestations of Korean patients with SSc and discusses the current trends in evidence-based treatment and recommendations.

Keyword

Systemic scleroderma; Epidemiology; Korea; Drug therapy

Figure

• 

  Fig. 1 The frequency of systemic sclerosis specific autoantibodies in patients with systemic sclerosis according to the countries. Scl70: anti-Scl70 antibody, ACA: anti-centromere antibody.

Reference

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). 1980; Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23:581–90.

2. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013; 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65:2737–47.

3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. 1988; Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 15:202–5.

4. LeRoy EC, Medsger TA Jr. 2001; Criteria for the classification of early systemic sclerosis. J Rheumatol. 28:1573–6.

5. Moon KW, Lee SS, Lee YJ, Jun JB, Yoo SJ, Ju JH, et al. 2018; Clinical and laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol. 45:1281–8.

6. Kang GW, Jung KH, Lee YS, Kim HJ, Yoon DY, Lee SH, et al. 2018; Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea: a nationwide population-based study. Br J Dermatol. 178:e37–9.

7. Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. 2020; An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 50:526–33.

8. Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M. 2021; Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 60:3121–33.

9. Andréasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. 2014; Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 73:1788–92.

10. Kim J, Park SK, Moon KW, Lee EY, Lee YJ, Song YW, et al. 2010; The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol. 29:297–302.

11. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. 2012; Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 51:1017–26.

12. Toledano E, Candelas G, Rosales Z, Martínez Prada C, León L, Abásolo L, et al. 2012; A meta-analysis of mortality in rheumatic diseases. Reumatol Clin. 8:334–41.

13. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. 2014; Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 44:208–19.

14. Poudel DR, Derk CT. 2018; Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol. 30:588–93.

15. Poudel DR, Jayakumar D, Danve A, Sehra ST, Derk CT. 2018; Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int. 38:1847–58.

16. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr. 2007; Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 34:104–9.

17. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, et al. 2008; The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 47:1185–92.

18. Hashimoto A, Tejima S, Tono T, Suzuki M, Tanaka S, Matsui T, et al. 2011; Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol. 38:1931–9.

19. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, et al. 2012; Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum. 41:789–800.

20. Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, et al. 2012; The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol. 39:2127–33.

21. Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, et al. 2015; Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis. 18:459–65.

22. Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, et al. 2017; Assessment of skin involvement in systemic sclerosis. Rheumatology (Oxford). 56(suppl 5):v53–66.

23. Volkmann ER, Furst DE. 2015; Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin North Am. 41:399–417.

24. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. 2017; Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2:11–8.

25. Park JW, Ahn GY, Kim JW, Park ES, Kang JH, Chang SH, et al. 2019; Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. Int J Rheum Dis. 22:96–102.

26. Zheng B, Nevskaya T, Baxter CA, Ramey DR, Pope JE, Baron M. Canadian Scleroderma Research Group. 2020; Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. Rheumatology (Oxford). 59:398–406.

27. Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, et al. 2019; Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 78:648–56.

28. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr. 2011; Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 70:104–9. Erratum.

29. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. 2007; Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 66:754–63.

30. Khanna SA, Nance JW, Suliman SA. 2022; Detection and monitoring of interstitial lung disease in patients with systemic sclerosis. Curr Rheumatol Rep. 24:166–73. Erratum.

31. Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A. 2021; Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 13:1759720X211037519.

32. Steen V. 2003; Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 62:97–9.

33. Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W. 2016; Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol. 26:588–93.

34. Ashmore P, Tikly M, Wong M, Ickinger C. 2018; Interstitial lung disease in South Africans with systemic sclerosis. Rheumatol Int. 38:657–62.

35. Jung E, Suh CH, Kim HA, Jung JY. 2018; Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch Rheumatol. 33:322–7.

36. Denton CP, Khanna D. 2017; Systemic sclerosis. Lancet. 390:1685–99.

37. Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. 2021; Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 80:219–27.

38. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. 2017; Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 69:1670–8.

39. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. 2008; Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 177:1248–54.

40. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. 2014; Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66:1625–35.

41. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. 2013; Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 52:155–60.

42. Bonhomme O, André B, Gester F, de Seny D, Moermans C, Struman I, et al. 2019; Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford). 58:1534–46.

43. Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. 2019; Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 21:58.

44. Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. 2020; Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol. 16:208–21. Erratum.

45. Hughes M, Herrick AL. 2017; Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 56:14–25.

46. Park EK, Lee SG, Kim BH, Park JH, Lee S, Kim GT. 2016; Insulin resistance is associated with digital ulcer in patients with systemic sclerosis. Clin Exp Rheumatol. 34 Suppl 100:85–91.

47. Kim E, Lee HN, Kim YK, Kim GT, So MW, Ahn E, et al. 2019; Increased serum uric acid levels are associated with digital ulcers in patients with systemic sclerosis. Rheumatol Int. 39:255–63.

48. Kim A, Kim Y, Kim GT, Ahn E, So MW, Sohn DH, et al. 2020; Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: cross-sectional analysis of data from a prospective cohort study. Rheumatol Int. 40:1071–9.

49. Kim HB, Kim A, Kim Y, Kim GT, Ahn E, So MW, et al. 2021; Associations of serum monocyte-to-high-density lipoprotein cholesterol ratio with digital ulcers and skin fibrosis in patients with systemic sclerosis. Scand J Rheumatol. 50:231–8.

50. Park EK, Park JH, Kweon SM, Kim GT, Lee SG. 2017; Vitamin D deficiency is associated with digital ulcer but not with atherosclerosis or arterial stiffness in patients with systemic sclerosis: a pilot study. Clin Rheumatol. 36:1325–33.

51. Rubio-Rivas M, Homs NA, Cuartero D, Corbella X. 2021; The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis. Autoimmun Rev. 20:102713.

52. Yoo SJ, Park JH, Park Y, Lee JH, Sun BJ, Kim J, et al. 2016; Prevalence of pulmonary arterial hypertension in Korean adult patients with systemic sclerosis: result of a pilot echocardiographic screening study. J Cardiovasc Ultrasound. 24:312–6.

53. Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R. 2021; Pulmonary hypertension phenotypes in patients with systemic sclerosis. Eur Respir Rev. 30:210053.

54. Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. 2010; Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 37:2290–8.

55. Giucă A, Mihai C, Jurcuț C, Gheorghiu AM, Groșeanu L, Dima A, et al. 2021; Screening for pulmonary hypertension in systemic sclerosis-a primer for cardio-rheumatology clinics. Diagnostics (Basel). 11:1013.

56. Fischer A, Bull TM, Steen VD. 2012; Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken). 64:303–10.

57. Yamane K, Ihn H, Asano Y, Yazawa N, Kubo M, Kikuchi K, et al. 2000; Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford). 39:1269–71.

58. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, et al. 2014; Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 146:1494–504.

59. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. 2014; Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 66:489–95.

60. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. 2013; Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 65:2412–23.

61. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. 2014; Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 73:1340–9.

62. Choi JH, Joo SJ, Kim J. 2016; Determining the necessity for right heart catheterization in pulmonary hypertension associated with connective tissue diseases assessed by echocardiography. Int J Rheum Dis. 19:65–73.

63. Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin Rev Allergy Immunol 2022 Jun 1 [Epub]. DOI:10.1007/s12016-022-08945-x.

64. Turk M, Pope JE. 2016; The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol. 43:1350–5.

65. Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, et al. 2018; Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev. 17:882–9.

66. Kim H, Lefebvre F, Hoa S, Hudson M. 2021; Mortality and morbidity in scleroderma renal crisis: a systematic literature review. J Scleroderma Relat Disord. 6:21–36.

67. Kumar S, Singh J, Rattan S, DiMarino AJ, Cohen S, Jimenez SA. 2017; Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 45:883–98.

68. Kaniecki T, Abdi T, McMahan ZH. 2021; A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. Best Pract Res Clin Rheumatol. 35:101666.

69. Lee KA, Choi W, Kim J, Kim HS. 2021; High prevalence of salivary gland ultrasound abnormalities in systemic sclerosis. Joint Bone Spine. 88:105113.

70. Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nuñez-Alvarez CA, Torrico-Lavayen R, García-Hernández JL, et al. 2011; Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity. 44:576–84.

71. Sampaio-Barros PD, Bortoluzzo AB, Marangoni RG, Rocha LF, Del Rio AP, Samara AM, et al. 2012; Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol. 39:1971–8.

72. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. 2013; Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 32:617–21.

73. Tahiat A, Allam I, Abdessemed A, Mellal Y, Nebbab R, Ladjouze-Rezig A, et al. 2020; Autoantibody profile in a cohort of Algerian patients with systemic sclerosis. Ann Biol Clin (Paris). 78:126–33.

74. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, et al. 2013; Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 52:143–54.

75. Onishi A, Sugiyama D, Kumagai S, Morinobu A. 2013; Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 65:1913–21.

76. Zhang JQ, Wan YN, Peng WJ, Yan JW, Li BZ, Mei B, et al. 2013; The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol. 37:523–7.

77. Kang KY, Yim HW, Kim IJ, Yoon JU, Ju JH, Kim HY, et al. 2009; Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 38:299–303.

78. Park JK, Yang JA, Ahn EY, Chang SH, Song YW, Curtis JR, et al. 2016; Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. BMC Cancer. 16:381.

79. Fragoulis GE, Daoussis D, Pagkopoulou E, Garyfallos A, Kitas GD, Dimitroulas T. 2020; Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. Expert Rev Clin Immunol. 16:1105–13.

80. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. 2010; Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 62:2787–95.

81. Colaci M, Giuggioli D, Sebastiani M, Manfredi A, Vacchi C, Spagnolo P, et al. 2013; Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev. 12:374–9.

82. Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, et al. 2018; Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis. 77:1179–86.

83. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. 2017; Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 76:1327–39.

84. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. 1996; Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 35:364–72.

85. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. 2001; A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44:1351–8.

86. Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K, et al. 2016; BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 55:1906–10.

87. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. 2012; A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 39:1241–7.

88. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. 2011; Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 70:1104–7.

89. Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. 2021; Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 3:e489–97.

90. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. 2007; Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 176:1026–34.

91. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. 2006; A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54:3962–70.

92. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. 2016; Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 4:708–19.

93. Fernández-Codina A, Walker KM, Pope JE. Scleroderma Algorithm Group. 2018; Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 70:1820–8.

94. Lee KA, Kim BY, Choi SJ, Kim SK, Kim SH, Kim HS. 2020; A real-world experience of mycophenolate mofetil for systemic sclerosis: a retrospective multicenter observational study. Arch Rheumatol. 35:366–75.

95. de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, de Oliveira VH, Pimenta IDSF, de Araújo IDT, et al. 2021; Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 61:15.

96. Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, et al. 2021; Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 73:1301–10.

97. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. 2014; Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 311:2490–8.

98. Kim N, Kim JS, Choi WH, Kim KH, Lee KA, Kim HS. 2021; Long-term evaluation of autologous hematopoietic stem cell transplantation in a patient with progressive systemic sclerosis. Arch Rheumatol. 36:308–10.

99. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. 2015; Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 45:1434–45.

100. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. 2019; Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 380:2518–28.

101. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. 2014; A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 370:2083–92. Erratum.

102. Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. 2020; Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 40:703–10.

103. Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, et al. 2022; The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study. Front Med (Lausanne). 9:871861.

104. Kwon HM, Kang EH, Park JK, Go DJ, Lee EY, Song YW, et al. 2015; A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 54:1792–6.

105. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. 2001; Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 44:1841–7.

106. Lee EY, Park JK, Lee W, Kim YK, Park CS, Giles JT, et al. 2014; Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford). 53:658–64.

107. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. 1992; Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 19:1407–14.

108. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. 1994; Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 120:199–206.

109. Tingey T, Shu J, Smuczek J, Pope J. 2013; Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 65:1460–71.

110. Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. 2016; Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 75:1009–15.

111. Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. 2010; Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 49:2420–8.

112. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. 2011; Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 70:32–8.

113. Chang SH, Jun JB, Lee YJ, Kang TY, Moon KW, Ju JH, et al. 2021; A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. Rheumatology (Oxford). 60:5814–9.

114. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, et al. 2007; Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 34:2417–22.

115. Galiè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, et al. 2017; Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol. 235:67–72.

116. Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, et al. 2018; The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. Pulm Circ. 8:2045893217748307.

117. Dees C, Beyer C, Distler A, Soare A, Zhang Y, Palumbo-Zerr K, et al. 2015; Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis. 74:1621–5.

118. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al. 2017; Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 76:422–6.

119. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. 2000; Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 132:425–34.

120. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, et al. 2004; Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 126:420–7.

121. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S, et al. 2001; Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol. 28:2252–6.

122. Steen VD, Medsger TA Jr. 2000; Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 133:600–3.

123. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. 1997; Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet. 349:620.

124. Gordon SM, Hughes JB, Nee R, Stitt RS, Bailey WT, Little DJ, et al. 2019; Systemic sclerosis medications and risk of scleroderma renal crisis. BMC Nephrol. 20:279.

125. Lynch BM, Stern EP, Ong V, Harber M, Burns A, Denton CP. 2016; UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol. 34 Suppl 100:106–9.

126. Lee JS, Kim HS, Moon JR, Ryu T, Hong SJ, Cho YS, et al. 2020; Esophageal involvement and determinants of perception of esophageal symptoms among South Koreans with systemic sclerosis. J Neurogastroenterol Motil. 26:477–85.

127. Frech TM, Mar D. 2018; Gastrointestinal and hepatic disease in systemic sclerosis. Rheum Dis Clin North Am. 44:15–28.

128. Gyger G, Baron M. 2012; Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 14:22–9.

129. McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, Saladini-Aponte C, et al. 2018; Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale). 8:235.

130. Zhong C, Qu C, Wang B, Liang S, Zeng B. 2017; Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence. J Clin Gastroenterol. 51:300–11.